AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00240331
First received: October 16, 2005
Last updated: May 17, 2011
Last verified: May 2011
  Purpose

The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.


Condition Intervention Phase
Renal Failure
Drug: 10mg Rosuvastatin
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Prevention
Official Title: A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events (AURORA). A Double Blind, Randomised, Phase 3b, Parallel-group Study to Compare the Effects of Rosuvastatin With Placebo on Assessment of Survival & Cardiovascular Events When Given to Subjects With End-stage Renal Failure on Chronic Haemodialysis Treatment

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death) [ Time Frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of Randomised Participants That Died From Any Cause. [ Time Frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
  • Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause [ Time Frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
  • Number of Randomised Participants That Died From Cardiovascular Cause [ Time Frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
  • Number of Randomised Participants That Died From Non Cardiovascular Cause [ Time Frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
  • Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death) [ Time Frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
  • Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis. [ Time Frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]
  • Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations). [ Time Frame: Events were reported continuously during the study. Duration of follow-up ranged from 1 day to 5.6 years ] [ Designated as safety issue: No ]

Enrollment: 2776
Study Start Date: January 2003
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rosuvastatin 10mg Drug: 10mg Rosuvastatin
Placebo Comparator: Placebo
matching Placebo
Drug: Placebo

  Eligibility

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects with end-stage renal failure aged 50-80 years, who have received regular haemodialysis treatment for at least 3 months

Exclusion Criteria:

  • Subjects will have no underlying condition that is expected to limit survival to less than 1 year and is also unrelated to end-stage renal disease (ESRD). Subjects should not have received a statin therapy within the past 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00240331

  Hide Study Locations
Locations
Australia, New South Wales
Research Site
St Leonards, New South Wales, Australia
Australia, Queensland
Research Site
Herston, Queensland, Australia
Austria
Research Site
Bregenz, Austria
Research Site
Feldkirch-Tisis, Austria
Research Site
Graz, Austria
Research Site
Innsbruck, Austria
Research Site
Linz, Austria
Research Site
St. Poelten, Austria
Research Site
Wels, Austria
Research Site
Wien, Austria
Belgium
Research Site
Aalst, Belgium
Research Site
Antwerpen, Belgium
Research Site
Brussels, Belgium
Research Site
La Louviere, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Brazil
Research Site
Curitiba, PR, Brazil
Research Site
Sao Paulo, SP, Brazil
Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Lethbridge, Alberta, Canada
Canada, British Columbia
Research Site
Kelowna, British Columbia, Canada
Research Site
Vancouver, British Columbia, Canada
Canada, Manitoba
Research Site
Winnipeg, Manitoba, Canada
Canada, New Brunswick
Research Site
Saint John, New Brunswick, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
London, Ontario, Canada
Research Site
Mississauga, Ontario, Canada
Research Site
Scarborough, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
York, Ontario, Canada
Canada, Quebec
Research Site
Greenfield Park, Quebec, Canada
Research Site
Laval, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Trois-Rivieres, Quebec, Canada
Canada
Research Site
Kitchener, Canada
Research Site
Rosemount, Canada
Czech Republic
Research Site
Hodonin, Czech Republic
Research Site
Hradec Kralove, Czech Republic
Research Site
Liberec, Czech Republic
Research Site
Pardubice, Czech Republic
Research Site
Praha 2, Czech Republic
Research Site
Praha 4, Czech Republic
Research Site
Praha 6, Czech Republic
Research Site
Tabor, Czech Republic
Research Site
Usti nad Labem, Czech Republic
Denmark
Research Site
Fredericia, Denmark
Research Site
Frederiksberg, Denmark
Research Site
Herlev, Denmark
Research Site
Holbaek, Denmark
Research Site
Horsens, Denmark
Research Site
København Ø, Denmark
Research Site
Roskilde, Denmark
Research Site
Rønne, Denmark
Research Site
Slagelse, Denmark
Research Site
Sønderborg, Denmark
Research Site
Viborg, Denmark
Finland
Research Site
Helsinki, Finland
Research Site
Hyvinkaa, Finland
Research Site
Joensuu, Finland
Research Site
Kotka, Finland
Research Site
Kuopio, Finland
Research Site
Lahti, Finland
Research Site
Oulu, Finland
Research Site
Pori, Finland
Research Site
Tammisaari, Finland
Research Site
Tampere, Finland
Research Site
Turku, Finland
France
Research Site
Amiens, France
Research Site
Annonay Cedex, France
Research Site
Aubervilliers, France
Research Site
Beauvais, France
Research Site
Bethune Cedex, France
Research Site
Boulogne Sur Mer, France
Research Site
Chambery, France
Research Site
Champigny Sur Marne, France
Research Site
Colmar Cedex, France
Research Site
Creil Cedex 1, France
Research Site
Evreux Cedex, France
Research Site
Fleury Merogis, France
Research Site
Foix Cedex, France
Research Site
Le Kremlin-Bicetre, France
Research Site
Maubeuge, France
Research Site
Meaux, France
Research Site
Mont de Marsan Cedex, France
Research Site
Montbonnot Saint Martin, France
Research Site
Nimes, France
Research Site
Olivet, France
Research Site
Paris, France
Research Site
Quimper Cedex, France
Research Site
Saint Maurice, France
Research Site
Saint Michel, France
Research Site
Tournan En Brie, France
Research Site
Valenciennes Cedex, France
Research Site
Vandoeuvre Les Nancy, France
Research Site
Vichy, France
Germany
Research Site
Ansbach, Germany
Research Site
Aschaffenburg, Germany
Research Site
Bad Münder, Germany
Research Site
Berlin, Germany
Research Site
Bischofswerda, Germany
Research Site
Dresden, Germany
Research Site
Duisburg, Germany
Research Site
Düsseldorf, Germany
Research Site
Erlangen, Germany
Research Site
Frankfurt, Germany
Research Site
Freiburg, Germany
Research Site
Greifswald, Germany
Research Site
Hann Münden, Germany
Research Site
Ingolstadt, Germany
Research Site
Jena, Germany
Research Site
Kaufbeuren, Germany
Research Site
Luedenscheid, Germany
Research Site
Marktheidenfeld, Germany
Research Site
München, Germany
Research Site
Pfarrkirchen, Germany
Research Site
Pirmasens, Germany
Research Site
Regensburg, Germany
Research Site
Rostock, Germany
Research Site
Saarbrucken, Germany
Research Site
Tangermünde, Germany
Research Site
Waldshut, Germany
Greece
Research Site
Alexandroupoli, Greece
Research Site
Athens, Greece
Research Site
Ioannina, Greece
Research Site
Thessaloniki, Greece
Research Site
Veroia, Greece
Hungary
Research Site
Budapest, Hungary
Research Site
Gyor, Hungary
Research Site
Miskolc, Hungary
Research Site
Nyiregyhaza, Hungary
Research Site
Szeged, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Veszprém, Hungary
Iceland
Research Site
Reykjavik, Iceland
Ireland
Research Site
Galway, Ireland
Italy
Research Site
Bergamo, BG, Italy
Research Site
Treviglio, BG, Italy
Research Site
Cremona, CR, Italy
Research Site
Genova, GE, Italy
Research Site
Lodi, LO, Italy
Research Site
Milano, Mi, Italy
Research Site
Rozzano, MI, Italy
Research Site
Reggio Calabria, RC, Italy
Research Site
Busto Arsizio, VA, Italy
Korea, Republic of
Research Site
Seongnam-Si, Korea, Korea, Republic of
Research Site
Seoul, Korea, Korea, Republic of
Mexico
Research Site
Mexico, D.f., Mexico
Research Site
Acapulco, Guerrero, Mexico
Research Site
Guadalajara, Jalisco, Mexico
Research Site
Cuernavaca, Morelos, Mexico
Research Site
Monterrey, Nuevo Leon, Mexico
Research Site
Distrito Federal, Mexico
Research Site
San Luis Potosi, Mexico
Netherlands
Research Site
Alkmaar, Netherlands
Research Site
Almelo, Netherlands
Research Site
Amersfoort, Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Arnhem, Netherlands
Research Site
Den Bosch, Netherlands
Research Site
Den Haag, Netherlands
Research Site
Deventer, Netherlands
Research Site
Dordrecht, Netherlands
Research Site
Emmen, Netherlands
Research Site
Groningen, Netherlands
Research Site
Leeuwarden, Netherlands
Research Site
Nieuwegein, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Sittard, Netherlands
Research Site
Tilburg, Netherlands
Norway
Research Site
Bergen, Norway
Research Site
Drammen, Norway
Research Site
Fredrikstad, Norway
Research Site
Lillehammer, Norway
Research Site
Lorenskog, Norway
Research Site
Oslo, Norway
Research Site
Skien, Norway
Research Site
Stavanger, Norway
Research Site
Trondheim, Norway
Research Site
Tønsberg, Norway
Poland
Research Site
Bialystok, Poland
Research Site
Gdansk, Poland
Research Site
Katowice, Poland
Research Site
Kraków, Poland
Research Site
Lublin, Poland
Research Site
Opole, Poland
Research Site
Plock, Poland
Research Site
Rybnik, Poland
Research Site
Wloclawek, Poland
Sweden
Research Site
Eksjö, Sweden
Research Site
Eskilstuna, Sweden
Research Site
Falun, Sweden
Research Site
Gävle, Sweden
Research Site
Göteborg, Sweden
Research Site
Jönköping, Sweden
Research Site
Karlstad, Sweden
Research Site
Linköping, Sweden
Research Site
Lund, Sweden
Research Site
Mölndal, Sweden
Research Site
Norrköping, Sweden
Research Site
Skövde, Sweden
Research Site
Stockholm, Sweden
Research Site
Trollhättan, Sweden
Research Site
Uppsala, Sweden
Research Site
Örebro, Sweden
Switzerland
Research Site
Aarau, Switzerland
Research Site
Bern, Switzerland
Research Site
Geneve, Switzerland
Research Site
Lausanne, Switzerland
Research Site
St. Gallen, Switzerland
Research Site
Zürich, Switzerland
Turkey
Research Site
Istanbul, Altunizade, Turkey
Research Site
Cebeci, Ankara, Turkey
Research Site
Kampus, Antalya, Turkey
Research Site
Antalya, Arapsuyu, Turkey
Research Site
Ankara, Besevler, Turkey
Research Site
Izmir, Bornova, Turkey
Research Site
Bursa, Gorukle, Turkey
Research Site
Istanbul, Haydarpasa, Turkey
United Kingdom
Research Site
Antrim, Northern Ireland, United Kingdom
Research Site
Belfast, Northern Ireland, United Kingdom
Research Site
Newry, Northern Ireland, United Kingdom
Research Site
Omagh, Northern Ireland, United Kingdom
Research Site
Bradford, United Kingdom
Research Site
Dumfries, United Kingdom
Research Site
Dundee, United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
Hull, United Kingdom
Research Site
Kilmarnock, United Kingdom
Research Site
Leeds, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Middlesborough, United Kingdom
Research Site
Newcastle, United Kingdom
Research Site
Plymouth, United Kingdom
Research Site
Rhyl, United Kingdom
Research Site
Sheffield, United Kingdom
Research Site
Surrey, United Kingdom
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Crestor Medical Sciences Director, MD AstraZeneca
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: MSD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00240331     History of Changes
Other Study ID Numbers: 4522IL/0096, D3562C00096
Study First Received: October 16, 2005
Results First Received: September 29, 2009
Last Updated: May 17, 2011
Health Authority: Sweden: Medical Products Agency

Keywords provided by AstraZeneca:
End Stage Renal Failure

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 23, 2014